DexCom Names Richard B. Doubleday Vice President of Sales

DexCom, Inc. (NASDAQ:DXCM) today announced that Richard B. Doubleday has been appointed to the position of Vice President of Sales where he will oversee DexCom’s sales and sales administration functions. Mr. Doubleday joins DexCom from Johnson & Johnson, where he spent over 21 years at several operating companies, including the past 13 years working in the diabetes space for both LifeScan, Inc. and Animas Corporation. Mr. Doubleday will report to Terry Gregg, DexCom’s President and Chief Executive Officer.

“We are delighted that Rick has agreed to lead our sales activities. Rick brings to DexCom not only a proven track record of sales leadership, but many professional working relationships in the diabetes community, which is consistent with my core belief that a strong commitment to diabetes is an essential part of building our business,” said Mr. Gregg. “He has demonstrated success in delivering exceptional results in organizational development, sales volume, alliance development, market share and profit growth and Rick has dedicated much of his career to improving the lives of people suffering with diabetes. We are coming into a critical time for DexCom as we lead healthcare providers and patients to an understanding of the full potential of continuous glucose monitoring in diabetes as well as in other key settings.”

Mr. Doubleday most recently worked as Director, Global Strategic Alliances for the Johnson & Johnson Family of Diabetes Companies. Mr. Doubleday joined Johnson & Johnson in May 1988 as a Retail Sales Representative with Advanced Care Products. He moved to LifeScan in 1996 as a National Account Manager. While at LifeScan, he also served as Area Manager, Consumer Sales, Field Sales Director, Consumer Sales, Field Sales Director, Professional Sales and Marketing Director, Health Care Professional Channel. In 2006, Mr. Doubleday moved to Animas Corporation as Director, Brand Marketing, responsible for promotion, positioning and messaging for new and existing products in the Animas portfolio. He then served as Director of Strategic Marketing and Alliances, responsible for developing and managing strategic alliances for Animas as well as helping to craft the long term portfolio strategy.

About DexCom, Inc.

DexCom, Inc., headquartered in San Diego, California, is developing and marketing continuous glucose monitoring systems for ambulatory use by patients and by healthcare providers in the hospital.

Cautionary Statement Regarding Forward Looking Statements

DexCom is a medical device company with a limited operating history. Successful commercialization of the company’s products is subject to numerous risks and uncertainties, including a lack of acceptance in the marketplace by physicians and patients, the inability to manufacture products in commercial quantities at an acceptable cost, possible delays in the company’s development programs, the inability of patients to receive reimbursement from third-party payors and inadequate financial and other resources. Certain of these risks and uncertainties, in addition to other risks, are more fully described in the company’s annual report on Form 10-Q for the period ending March 31, 2009, as filed with the Securities and Exchange Commission on May 6, 2009.